SCHEMBL4187658

SCHEMBL4187658

O=C(Cc1ccccc1)c1c(O)c2cccnc2n(-c2cccc(C(F)(F)F)c2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.47
TP53 P04637 1/20 0.47
TRPV1 Q8NER1 1/20 0.43
LMNA P02545 1/20 0.43
PDE4B Q07343 1/20 0.41
PDE4D Q08499 1/20 0.41
PPARG P37231 1/20 0.41
PDE1A P54750 1/20 0.41
PDE1B Q01064 1/20 0.41
CCKBR P32239 1/20 0.40
PDE4A P27815 1/20 0.40
CCR1 P32246 1/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
THRB P10828 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
FEN1 P39748 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4183574 0.95 TP53 (0.44) POLBTP53TRPV1LMNAPDE4B
SCHEMBL4185752 0.94 TP53 (0.47) POLBTP53TRPV1LMNAPDE4B
SCHEMBL4183644 0.94 TP53 (0.43) POLBTP53TRPV1LMNAPDE4B
SCHEMBL4195071 0.93 CNR2 (0.44) POLBTP53TRPV1LMNAPDE4B
SCHEMBL13685422 0.92 TP53 (0.40) POLBTP53TRPV1LMNAPDE4B
SCHEMBL4189465 0.89 BCL2L1 (0.42) POLBTP53TRPV1PDE4BPDE4D
SCHEMBL13685423 0.89 PDE4A (0.42) POLBTP53PDE4BPDE4DPDE1A
SCHEMBL4190734 0.89 PPARG (0.41) POLBTP53TRPV1PDE4BPDE4D
SCHEMBL4187214 0.88 POLB (0.45) POLBTP53TRPV1LMNAPDE4B
SCHEMBL4187633 0.88 PPARG (0.41) POLBTP53TRPV1PDE4BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925617-B1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA PHARM CO LTD (JP) 2012-11-14 EP disclosed
US-8193356-B2 Heterocycle compound, and production process and application thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-05 US disclosed
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1925617-A1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA Pharmaceutical Co., Ltd. (JP) 2008-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof PDE3B, PDE4B, PDE7A POLB 1630/4885TP53 4856/4885TRPV1 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.